Business
Voyageur Completes Human Testing of Barium Contrast Products and Prepares for Canadian Market Launch
(TheNewswire) Calgary, Alberta, Canada – April 1, 2025 – TheNewsw...
About this update from Voyageur Pharmaceuticals Ltd
[{"type":"text","content":"Voyageur Completes Human Testing of Barium Contrast Products and Prepares for Canadian Market Launch \n\n\n (TheNewswire)\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n Calgary, Alberta, Canada – April 1, 2025 –\n \n\n TheNewswire -\n \n\n Voyageur\nPharmaceuticals Ltd.\n \n\n (TSX.V:VM) (OTC Pink:VYYRF)\n(\"\n \n\n Voyageur\n \n\n \" or the \"\n \n\n Company\n \n\n \") is pleased to announce the\nsuccessful completion of a key phase in human testing of its Health\nCanada-licensed barium contrast media product suite. This milestone\npaves the way for Voyageur’s upcoming product launch across the\nCandain market.\n \n\n\n\n A total of 24 test subjects participated in the phase\none program, which involved oral administration of Voyageurs contrast\nagents, followed by diagnostic imaging procedures. Four of\nVoyageur’s licensed barium contrast media products (SmoothLD®,\nSmoothHD®, VisionHD®, and VisionLD®) were used in these\nevaluations. The images generated are currently undergoing final\nanalysis by Voyageurs team of radiology experts and its Scientific\nAdvisory Board, who are assessing both quantitative and qualitative\nimaging performance, including diagnostic clarity and overall image\nquality.\n \n\n\n\n Final performance review is expected to be completed\nwithin 30 days. Following this, Voyageur will begin market testing and\ninitial commercial sales in Canada. Discussions are also underway with\ninternational distribution partners in jurisdictions that recognize\nHealth Canada licensed medical products.\n \n\n\n\n Upon Canadian market entry, Voyageur will initiate\nphase two testing to support FDA licensing under the 505(2)(b)\npathway. This next phase will generate clinical and operational data\nfocused on key performance indicators, including\n \n\n safety, efficacy, pharmacokinetic, pharmacodynamics,\nregulatory compliance and market readiness.\n \n\n\n\n Voyageur’s proprietary contrast media formulations\nare engineered to deliver superior image clarity for gastrointestinal\nradiographic procedures across adult and pediatric populations. The\nCompany’s focus on innovation, image quality and patient safety\npositions it as a key player in the evolving global contrast media\nmarket.\n \n\n\n\n Diagnostic centres interested in integ...